Biora Therapeutics, Inc.
Biora Therapeutics is innovating smart-pill technologies designed to deliver the right dose to the right place, safely. Their mission is to reimagine therapeutic delivery through advanced oral delivery platforms like BioJet™ and NaviCap™, aiming to replace injections and improve management of chronic diseases.
Industries
Nr. of Employees
medium (51-250)
Patents
Assessment of preeclampsia using assays for free and dissociated placental growth factor
US-11327071-B2
View DetailsIngestible device for delivery of therapeutic agent to the gastrointestinal tract
US-11007356-B2
View Details
Assessment of preeclampsia using assays for free and dissociated placental growth factor
US-11327071-B2
View DetailsIngestible device for delivery of therapeutic agent to the gastrointestinal tract
US-11007356-B2
View DetailsProducts
Needle-free oral biotherapeutic delivery platform
A platform intended to administer large-molecule therapeutics orally without needles to achieve systemic exposure as an alternative to injection.
Targeted oral delivery system for colonic mucosa
An oral delivery system designed to localize and release therapeutic compounds directly to the colonic mucosa to improve local efficacy and reduce systemic exposure, intended for conditions such as ulcerative colitis.
Needle-free oral biotherapeutic delivery platform
A platform intended to administer large-molecule therapeutics orally without needles to achieve systemic exposure as an alternative to injection.
Targeted oral delivery system for colonic mucosa
An oral delivery system designed to localize and release therapeutic compounds directly to the colonic mucosa to improve local efficacy and reduce systemic exposure, intended for conditions such as ulcerative colitis.
Services
Design and conduct of clinical studies to evaluate device function, safety, tolerability, and early pharmacokinetics of drug–device combination products in healthy volunteers and patient populations.
Preclinical assessment of pharmacokinetics for biologics delivered via oral delivery platforms using large-animal models and studies of formulation/food effects to inform clinical translation.
Design and conduct of clinical studies to evaluate device function, safety, tolerability, and early pharmacokinetics of drug–device combination products in healthy volunteers and patient populations.
Preclinical assessment of pharmacokinetics for biologics delivered via oral delivery platforms using large-animal models and studies of formulation/food effects to inform clinical translation.
Expertise Areas
- Targeted oral drug delivery
- Combination drug–device development
- Phase I clinical trial conduct
- Preclinical pharmacokinetics in large-animal models
Key Technologies
- Needle-free oral biotherapeutic delivery
- Targeted colonic delivery devices
- Drug–device combination platforms
- Large-animal pharmacokinetic studies
News & Updates
Results from a Phase 1 clinical trial of BT-600, a product combining NaviCap™ targeted oral delivery platform and tofacitinib.
Study results on the human device function of NaviCap™ platform in healthy volunteers and UC patients.
An update on pharmacokinetics of GLP-1 receptor agonist delivered via BioJet™ platform in a pig model.
Study on pharmacokinetics of GLP-1 receptor agonist using BioJet™ platform in pigs.
Study on how food affects a new DDS for delivering drugs into the colon.
Development of a DDS for targeted drug delivery to the colon for UC treatment.
Results from a Phase 1 clinical trial of BT-600, a product combining NaviCap™ targeted oral delivery platform and tofacitinib.
Study results on the human device function of NaviCap™ platform in healthy volunteers and UC patients.
An update on pharmacokinetics of GLP-1 receptor agonist delivered via BioJet™ platform in a pig model.
Study on pharmacokinetics of GLP-1 receptor agonist using BioJet™ platform in pigs.
Study on how food affects a new DDS for delivering drugs into the colon.
Development of a DDS for targeted drug delivery to the colon for UC treatment.